6sense

Belkins
6sense’s Account Based Orchestration Platform helps revenue teams compete and win in the age of Account Based Buying by putting the power of AI, big data and machine learning behind every member of the B2B revenue team, empowering them to uncover anonymous buying behavior, prioritize fragmented data to focus on accounts in market, and engage resistant buying teams with personalized, omni-channel, multi-touch campaigns. 6sense helps revenue teams know everything they need to know about their buyers so they can easily do anything they need to do to generate more opportunities, increase deal size, get into opportunities sooner, compete and win more often.

C-Suite On Deck

Latane Conant, CMO at 6sense has always been keenly focused on leveraging data to ensure marketing programs result in deals, not just leads.

At 6sense, Latane helps sales and marketing leaders increase revenue by tapping into the power of predictive intelligence to u...

Events

Related News

RESEARCH

TETRASCIENCE R&D DATA CLOUD SELECTED BY LEADING CLINICAL-STAGE BIOTECHNOLOGY COMPANY

TetraScience | September 03, 2021

news image

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data sc...

Read More

MEDICAL

BIOAGILYTIX TO PURCHASE AUSTRALIA-BASED 360BIOLABS®

BioAgilytix | August 17, 2021

news image

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...

Read More

GENSCRIPT FILES FOR EMERGENCY USE AUTHORIZATION OF RAPID SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript | June 03, 2020

news image

GenScript Biotech Corp., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first test submitted for regulatory approval that specifically detects neutralizing antibodies to SARS-CoV-2, the virus that causes COV-19, without the use of live virus. Current serological antibody tests...

Read More

MEDTECH

TAVOTEK BIOTHERAPEUTICS ANNOUNCES COMPLETION OF ROUND B FINANCING WITH $35 MILLION

Tavotek | November 19, 2021

news image

Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders. In addit...

Read More

RESEARCH

TetraScience | September 03, 2021

news image

TETRASCIENCE R&D DATA CLOUD SELECTED BY LEADING CLINICAL-STAGE BIOTECHNOLOGY COMPANY

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data sc...

Read More

MEDICAL

BioAgilytix | August 17, 2021

news image

BIOAGILYTIX TO PURCHASE AUSTRALIA-BASED 360BIOLABS®

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...

Read More

GenScript | June 03, 2020

news image

GENSCRIPT FILES FOR EMERGENCY USE AUTHORIZATION OF RAPID SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript Biotech Corp., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first test submitted for regulatory approval that specifically detects neutralizing antibodies to SARS-CoV-2, the virus that causes COV-19, without the use of live virus. Current serological antibody tests...

Read More

MEDTECH

Tavotek | November 19, 2021

news image

TAVOTEK BIOTHERAPEUTICS ANNOUNCES COMPLETION OF ROUND B FINANCING WITH $35 MILLION

Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders. In addit...

Read More